This systematic review and network meta-analysis of 14 large-scale RCTs, encompassing over 117,000 patients, provides a comprehensive synthesis of the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists on cardiorenal outcomes in patients with T2DM. Here, GLP1R is linked to type 2 diabetes mellitus.